

Platelet count and parasite density: Independent variable in *Plasmodium vivax* malaria

Dhanpat Kumar Kochar¹, Gajanand Singh Tanwar², Renu Agrawal², Shilpi Kochar¹, Gayatri Tanwar¹, Swati Kochar Falodia³, Abhishek Kochar³, Sheetal Middha³ & Sanjay Kumar Kochar³

¹Malaria Research Center, Kothari Medical & Research Institute, Bikaner; ²Department of Pediatrics, S.P. Medical College, Bikaner; ³Malaria Research Clinic, S.P. Medical College, Bikaner, India

Key words Parasite density; *Plasmodium vivax*; platelet; thrombocytopenia

The occurrence of thrombocytopenia in *Plasmodium vivax* malaria is well-documented. In spite of being a common observation, its prognostic implications in context with parasite density has not been evaluated. In view of the paucity of data, we attempted to study the correlation of platelet count with parasite density in *P. vivax* mono-infection.

This prospective study was carried out on patients attending outpatient clinic from June 2011 to December 2011. The study was conducted on patients coming to outpatient department at the time of first consultation for fever in which diagnosis of *P. vivax* mono-infection was made by peripheral blood smear (PBS) and rapid diagnostic test (RDT). Patients having severe malarial manifestations were enrolled in another observational study (under process) and confirmation of malarial species in them was made by PCR analysis. Due to inclusion of large number of patients in the present study, we used an 'OptiMAL[®] Rapid Malaria Dipstick Test' to rule out concomitant low density *P. falciparum* mixed infection. This test detects the presence of *Plasmodium* lactate dehydrogenase (pLDH); an enzyme produced both by the sexual and asexual forms of the parasite. The presence of pLDH is revealed using monoclonal antibodies directed against isoforms of the enzyme. This test detects parasitemia levels of 100–200 parasites per μl of blood (corresponding to a parasitemia of 0.002–0.004%). Another point against the presence of associated *P. falciparum* infection is that such a low parasitemia of *P. falciparum* so as to be undetectable both by the dipstick test and standard microscopy, is highly unlikely to cause such profound thrombocytopenia.

The possibilities of other concurrent similar illness causing thrombocytopenia were ruled out by appropriate and stringent laboratory investigations. Details are given in our previous study¹. Platelet count was done by fully

automated counter and the results were derived from directly measured platelet pulses, multiplied by a calibration constant and expressed in 1000 thrombocytes/ μl of whole blood. A written informed consent was mandatory and those who refused to give the written consent or had other concurrent illness were not included in the study.

This study includes 599 patients of *P. vivax* mono-infection, but parasite density was done only in 546 patients fulfilling the eligibility criteria. The age distribution range included in the study was 1–60 yr and sex ratio was 2.33 (male : female = 382 : 164). The mean \pm SD platelet count and mean \pm SD parasite density were 90199.6 ± 57414.9 and 6733.4 ± 9523.8 , respectively. Thrombocytopenia ($<150,000/\text{mm}^3$) was present in 85.71% (468/546) patients with a mean platelet count of 72715.8 ± 38625.4 . Statistical analysis done by correlation coefficient did not show any association between platelet count and parasite load [correlation coefficient (R^2) = 0.000] (Fig. 1). All these patients were treated as per WHO guidelines.




Fig. 1: Statistical association of platelet count with *P. vivax* parasite load

The exact mechanism of thrombocytopenia in malaria is not clear. The commonly reported mechanisms are decreased life span of platelets due to immunological and non-immunological mechanisms, elevated macrophage colony stimulating factors causing platelet destruction; ultra structural changes like centralization of dense granules, glycogen depletion, formation of pseudopods, and micro aggregation; consumption by diffused intravascular coagulation (DIC) host oxidative stress through oxidation of membrane lipids causing changes in fluidity and permeability of the cell membrane and its effect on fragility^{2,3}. Another mechanism had also been postulated about removing of platelets from the circulation by consumption in intravascular coagulation, and depletion of coagulation factors and the presence of fibrinogen degradation products as well as thrombocytopenia parasite density⁴⁻⁶. Whether the consumption of platelet is the result of host defence mechanism or vice versa is a matter of debate⁷.

Although an inverse relationship between elevated parasite levels and decreased platelet counts has been reported for *P. vivax* infection previously⁸, this observational study illustrates statistically that platelet count in a patient of *P. vivax* mono-infection has no relation with parasite load in the patient. Whatever the malarial parasite load is there, platelet count despite the result of either both immunological and non-immunological mechanisms or host

defense mechanism, not yet clear, definitely doesn't depend on parasite load. In other words, it is also true that parasite load is not true predictor of changes in platelet count.

REFERENCES

1. Kochar DK, Das A, Kochar A, Middha S, Acharya J, Tanwar GS, *et al.* Thrombocytopenia in *Plasmodium falciparum*, *Plasmodium vivax* and mixed infection malaria: A study from Bikaner (northwestern India). *Platelets* 2010; 21(8): 623-7.
2. Mehrunnisa A, Wajihullah, Saifi NA, Khan HM. Prevalence of malaria. *J Commun Dis* 2002; 34: 70-7.
3. Park JW, Park SH, Yeom JS. Serum cytokine profiles in patients with *Plasmodium vivax* malaria: A comparison between those who presented with or without thrombocytopenia. *Am J Trop Med Parasitol* 2003; 97(4): 339-44.
4. Jadhav UM, Patkar VS, Kadam NN. Thrombocytopenia in malaria-correlation with type and severity of malaria. *J Assoc Physicians India* 2004; 52: 615-8.
5. Erel O, Kocyigit A, Avci S, Aktepe N, Bulut V. Oxidative stress and antioxidative status of plasma and erythrocytes in patients with *vivax* malaria. *Clin Biochem* 1997; 30(8): 631-9.
6. Elawad MEH, Jobaran JM, Duya AA. Immunoglobulin therapy for severe thrombocytopenia complicating *falciparum* malaria. *Trop Med Int Health* 1999; 4(12): 812-3.
7. Greenbaum DC, FitzGerald GA. Platelets, pyrexia, and plasmodia. *N Engl J Med* 2009; 361(5): 526-8.
8. Erhart LM, Yingyuen K, Chuanak N, Buathong N, Laoboonthai A, Miller RS, *et al.* Hematologic and clinical indices of malaria in a semi-immune population of western Thailand. *Am J Trop Med Hyg* 2004; 70: 8-14.

Correspondence to: Dr D.K. Kochar, C-54, Sadul Ganj, Bikaner-334 003, Rajasthan, India.
E-mail: drdkkochar@yahoo.com; drdkkochar@indiatimes.com

Received: 30 January 2012

Accepted in revised form: 22 August 2012